Investors & Media

Transformative science, targeted medicines

Blueprint Medicines is a fully integrated global biopharmaceutical company that invents life-changing medicines across two strategic focus areas of allergy/inflammation and oncology/hematology. Our approach combines deep scientific expertise, modality-agnostic drug discovery capabilities, and a proven track record of R&D success. Currently, we are commercializing our approved medicine AYVAKIT/AYVAKYT® (avapritinib) in the U.S. and Europe, as well as in other regions of the world through partnerships.

SEC Filings

SEC Filings

Search
Filing date Form Description View
4

Statement of changes in beneficial ownership of securities

 View HTML
0001179110-19-003446.pdf
0001179110-19-003446.rtf
4

Statement of changes in beneficial ownership of securities

 View HTML
0001179110-19-003306.pdf
0001179110-19-003306.rtf
4

Statement of changes in beneficial ownership of securities

 View HTML
0001179110-19-003309.pdf
0001179110-19-003309.rtf
4

Statement of changes in beneficial ownership of securities

 View HTML
0001179110-19-003308.pdf
0001179110-19-003308.rtf
4

Statement of changes in beneficial ownership of securities

 View HTML
0001179110-19-003307.pdf
0001179110-19-003307.rtf
4

Statement of changes in beneficial ownership of securities

 View HTML
0001179110-19-003312.pdf
0001179110-19-003312.rtf
4

Statement of changes in beneficial ownership of securities

 View HTML
0001179110-19-003311.pdf
0001179110-19-003311.rtf
4

Statement of changes in beneficial ownership of securities

 View HTML
0001179110-19-003314.pdf
0001179110-19-003314.rtf
4

Statement of changes in beneficial ownership of securities

 View HTML
0001179110-19-003315.pdf
0001179110-19-003315.rtf
8-K

Report of unscheduled material events or corporate event

 View HTML
0001558370-19-001039.pdf
0001558370-19-001039.rtf
0001558370-19-001039.xls